Evolving Landscape of Respiratory Viral Infections in Hematopoietic Cellular and CAR T-cell Therapy Recipients Post-COVID-19 Pandemic
Posted inHematology-Oncology Infectious Diseases news

Evolving Landscape of Respiratory Viral Infections in Hematopoietic Cellular and CAR T-cell Therapy Recipients Post-COVID-19 Pandemic

This study elucidates the incidence and characteristics of respiratory viral infections (RVIs) within 100 days following hematopoietic cell transplant and CAR T-cell therapy, highlighting SARS-CoV-2 as the predominant pathogen and identifying risk factors for severe infection in the post-pandemic era.
ATG Versus ATG Plus Post-Transplant Cyclophosphamide: A Pilot Trial for GvHD Prophylaxis in Matched Donor Hematopoietic Cell Transplants
Posted inHematology-Oncology news

ATG Versus ATG Plus Post-Transplant Cyclophosphamide: A Pilot Trial for GvHD Prophylaxis in Matched Donor Hematopoietic Cell Transplants

A randomized pilot trial shows comparable survival and safety outcomes for anti-thymocyte globulin alone versus combined with post-transplant cyclophosphamide, supporting further phase III investigation for graft-versus-host disease prophylaxis in matched donor hematopoietic cell transplantation.